Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.